Objective: Video-assisted thoracic surgery (VATS) lobectomy was introduced over 25 years ago. More recently, the technique has been modified from a multiport video-assisted thoracic surgery (mVATS) to uniportal (uVATS) and robotic (rVATS), with proponents for each approach. Additionally most lobectomies are still performed using an open approach. We sought to provide evidence-based recommendations to help define the optimal surgical approach to lobectomy for early stage non-small cell lung cancer. Methods: Systematic review and meta-analysis of articles searched without limits from January 2000 to January 2018 comparing open, mVATS, uVATS, and rVATS using sources Medline, Embase, and Cochrane Library were considered for inclusion. Articles were individually scrutinized by ISMICS consensus conference members, and evidence-based statements were created and consensus processes were used to determine the ensuing recommendations. The ACC/AHA Clinical Practice Guideline Recommendation Classification system was used to assess the overall quality of evidence and the strength of recommendations. Results and recommendations: One hundred and forty-five studies met the predefined inclusion criteria and were included in the meta-analysis. Comparisons were analyzed between VATS and open, and between different VATS approaches looking at oncological outcomes (survival, recurrence, lymph node evaluation), safety (adverse events), function (pain, quality of life, pulmonary function), and cost-effectiveness. Fifteen statements addressing these areas achieved consensus. The highest level of evidence suggested that mVATS is preferable to open lobectomy with lower adverse events (36% versus 42%; 88,460 patients) and less pain (IIa recommendation). Our meta-analysis suggested that overall survival was better (IIb) with mVATS compared with open (71.5% versus 66.7% 5-years; 16,200 patients). Different VATS approaches were similar for most outcomes, although uVATS may be associated with less pain and analgesic requirements (IIb). Conclusions: This meta-analysis supports the role of VATS lobectomy for non-small cell lung cancer. Apart from potentially less pain and analgesic requirement with uVATS, different minimally invasive surgical approaches appear to have similar outcomes. 
Introduction
Lobectomy remains the standard treatment for resectable early stage non-small cell lung cancer (NSCLC). Since the first description of video-assisted thoracic surgery (VATS) lobectomy in 1992, 1 the technique has been under the spotlight and scrutiny. There are numerous reported advantages of the VATS technique when compared with open thoracotomy, including less perioperative blood transfusion, less pain, shorter hospital stay, better cosmesis, an attenuated inflammatory-immune response, and even reports of improved long-term survival. However high level evidence, particularly in the form of randomized trials, is lacking. Nevertheless, VATS lobectomy for resectable early stage NSCLC is currently recommended as the surgical approach of choice in numerous guidelines. More recently minimally invasive lobectomy can be performed by the uniportal VATS (uVATS) and robotic VATS (rVATS) approaches, providing more surgical options but complicating the debate on the optimal approach to lobectomy. Potential advantages of uVATS include less pain from fewer intercostal space incisions when compared with conventional multiport VATS (mVATS) lobectomy. Advocates of rVATS on the other hand champion the robot system's high definition 3-dimensional vision, range of movement, and dexterity for allowing more precise surgery and the benefits that this may entail. The International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) produced a consensus statement in 2007 on video-assisted thoracic surgery for lung cancer resection. 2 By assessing the best available evidence for VATS and open thoracotomy approaches to lobectomy, statements and recommendations for patients with clinical stage I NSCLC undergoing lung lobectomy were agreed. More than a decade later, with the evolution of newer minimally invasive thoracic surgical options for lobectomy, a consensus conference was again organized to systematically evaluate the relative advantages and disadvantages of open, mVATS, uVATS, and rVATS lobectomy.
Objectives
We investigated surgical approaches for lobectomy for NSCLC. Our aim was to determine the optimal surgical approach when lobectomy is performed and assess whether minimally invasive surgical (MIS) approaches including multiport video-assisted thoracic surgery (mVATS), uniportal video-assisted thoracic surgery (uVATS), and robotic video-assisted thoracic surgery (rVATS) improve clinical and resource outcomes compared to conventional open lobectomy. We also sought to determine whether there were differences between minimally invasive surgical approaches to lobectomy.
Inclusion Criteria
Randomized controlled trials (RCTs), and nonrandomized observational studies including prospective or retrospective cohort and case-control studies were considered for inclusion. Adult patients undergoing upfront lobectomy for stages I-III NSCLC were considered for inclusion. Studies comparing VATS (mVATS, rVATS, or uVATS) to conventional open thoracotomy, as well as studies that compared mVATS to rVATS or uVATS were included. For the purposes of this study and analysis any VATS lobectomy using more than one port was considered to be multiport VATS. Studies that assessed other types of surgery including segmentectomy, bilobectomy, sleeve lobectomy, pneumonectomy, and wedge resection were excluded. However, we included studies reporting mixed lung resection procedures, when data extraction and analysis of outcomes for lobectomy for NSCLC patients could be segregated out. We also excluded studies where patients received neoadjuvant chemotherapy or radiation, studies that included patients with advanced lung cancer, and studies that included patients with benign neoplasm or infectious disease (e.g., tuberculosis). We made one post hoc exception for inclusion. There were so few studies that reported on cost data specifically after lobectomy for NSCLC, that cost studies that included other types of VATS resection and studies where patients received VATS for a lung condition other than NSCLC were included.
Data Extraction and Management
A standardized data extraction sheet was developed to record the following data from the included studies: study design, number of patients, inclusion and exclusion criteria, details on the VATS procedure and the comparative surgical procedure, primary and secondary outcome measures, and duration of follow-up. At least 2 authors independently extracted outcome data. Any discrepancies were resolved by discussion and consensus.
Assessment of Methodological Quality
We used the Cochrane Collaboration risk of bias tool to assess the methodological quality of RCTs. 4 Factors that were assessed included: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias. Based on these factors we rated the studies as low, unclear, or high risk of bias. We contacted study authors for additional information if any items being assessed were unclear. We assessed the methodological quality of cohort and case-control studies using the Newcastle-Ottawa Scale. 5 
Data Analysis
Data from individual trials were pooled for meta-analysis if the interventions, patient groups, and outcomes were sufficiently similar (determined by consensus). For dichotomous outcomes we calculated the odds ratio (OR) and corresponding 95% confidence interval (95% CI). For continuous outcomes, we calculated the mean difference (MD) and corresponding 95% CI. If different scales were used to measure the same underlying construct, we calculated the standardized mean difference (SMD) and corresponding 95% CI as appropriate. Meta-analysis was carried out using a random-effects model. A statistically significant overall effect was defined as P < 0.05 or as a 95% CI that did not cross the line of no effect (i.e., 1 for OR and 0 for MD or SMD). We assessed heterogeneity among studies using the chisquare test. A P value of ≤0.10 was regarded as statistically significant for the chi-square test. The I 2 statistic was used to quantify heterogeneity. This statistic describes the percentage of total variation across studies that results from heterogeneity rather than chance. A value of 25% is considered to indicate low heterogeneity, 50% moderate heterogeneity, and 75% high heterogeneity. 6 We explored publication bias through visual inspection of funnel plots as appropriate (i.e., when 10 or more studies were included in a pooled analysis). We used the Cochrane Collaboration Review Manager software (RevMan version 5.3) for the statistical analysis. 7 
Consensus Conference
A consensus conference was organized by ISMICS to determine the optimal surgical approach for lobectomy in NSCLC and whether minimally invasive surgical approaches including mVATS, rVATS, and uVATS improve clinical and resource outcomes compared to conventional open lobectomy. In addition, we sought to identify the superior minimally invasive surgical approach to lobectomy. The consensus conference panel members were selected based on content and/ or methodologic expertise. An additional panel member (JKM) was invited based on his expertise in evidence-based medicine, systematic reviews, and meta-analysis. The ACC/AHA Clinical Practice Guideline Recommendation Classification system was used to assess the overall quality of evidence and the strength of recommendations.
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Results
The literature search identified 16,861 records. Eight records were identified through other sources including searching the reference sections of systematic reviews. After duplicates were removed, a total of 12,678 studies remained for review of titles and abstracts. After the titles and abstracts of these trials were reviewed 330 studies were selected for full text review (Fig. 1) . One hundred and sixty-one publications (reports) from 150 studies were excluded (see online Appendix 2). Fifty-two studies were excluded because no usable data were reported. Fifty-seven studies were excluded because other types of surgery including segmentectomy, bilobectomy, sleeve lobectomy, pneumonectomy, or wedge resection were assessed without separate results being reported for lobectomy. Nineteen studies were excluded because some or all patients received neoadjuvant chemotherapy or radiation. Nine studies were excluded because patients without NSCLC were included without reporting separate results for patients with NSCLC. Two studies were excluded because these studies only included patients with advanced lung cancer. Two excluded studies were published protocols for RCTs. Three studies did not report on prespecified outcomes. One study was an RCT that compared rVATS to mVATS. This study was excluded because it only reported results for the rVATS group. Park et al. was excluded because of poor quality surgery and the study was stopped early. Donahoe et al. was a retrospective cohort study comparing survival and complications in high risk and low risk lobectomy patients. Jung et al. was an RCT comparing the use of apneic oxygen insufflation to no apneic oxygen insufflation in patients receiving lobectomy. These two studies were excluded because patients in both comparison groups had VATS or open surgery. One study was excluded because it compared two-port VATS to three-port VATS.
One hundred and sixty-nine reports of 145 studies met the predefined inclusion criteria and were included in the review. Seven studies were RCTs and included a total of 1,276 randomized patients, 19, 94, 111, 126, 168, 169, 171 and 138 studies including a total of 368,517 patients were nonrandomized cohort and case-control studies. In total the 145 studies included 369,793 patients. Three studies were published in languages other than English. 100, 113, 168 The characteristics of the included studies are reported in Table 1 . One hundred and fifteen studies compared mVATS to open lobectomy. 9, 10, [12] [13] [14] [15] [18] [19] [20] 22, 23, [25] [26] [27] [29] [30] [31] [32] [33] [34] [38] [39] [40] [41] [42] [44] [45] [46] [47] 49, 51, 54, 56, 60, 62, 63, [65] [66] [67] [68] [69] 71, 73, [75] [76] [77] 80, 84, 86, 87, 89, 90, 92, 94, [96] [97] [98] [99] [100] [101] [102] [103] [104] [106] [107] [108] [109] [110] [111] 114, 115, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 119, [121] [122] [123] [124] [125] [127] [128] [129] [130] [131] 133, 134, 136, 137, 139, 140, 143, 144, 146, [148] [149] [150] [151] [152] [153] [155] [156] [157] [158] [160] [161] [162] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] 176 Nine studies compared mVATS to rVATS. 18, 21, 36, 50, 61, 81, 85, 95, 147 Thirteen studies compared mVATS to uVATS. 35, 53, 57, 59, 70, 72, 91, 93, 126, 138, 141, 142, 177 One study compared rVATS to open lobectomy. 154 One study compared uVATS to open lobectomy. 88 Four studies compared mVATS to rVATS and open lobectomy. 37, 116, 132, 164 Two studies compared minimally invasive surgery (mVATS and rVATS combined) to open lobectomy. 159, 163 Thirty-four studies used propensity matching to control for confounders. 10, 18, 20, 27, 35, 39, 42, 59, 63, 71, 72, 76, 84, 101, 104, 109, 110, 115, 119, [121] [122] [123] 132, 134, 138, 144, 147, 154, 156, [162] [163] [164] 167, 172 Although most of the studies were conducted in the United States, China, Japan, and South Korea, several European countries and one South American country were also represented.
The risk of bias assessment for the seven RCTs is reported in Fig. 2 . All of the RCTs were rated as high risk of bias for blinding. The methodological quality assessment (Newcastle-Ottawa scale) of the 138 nonrandomized studies identified by the updated literature search is reported in Table 2 . Total scores on this scale can range from a value of 0 to 9 with nine indicating high methodological quality. Most of the studies were judged to be of reasonably good quality with 9 studies receiving scores of 9, 23 studies receiving scores of 8, 38 studies receiving scores of 7, 21 studies receiving scores of 6, 29 studies receiving scores of 5, 6 studies receiving scores of 4 and 14 studies receiving scores of 3. One study was not assessed because it was published in Japanese. 100 Although all of the included studies were at risk for performance or detection bias because it was not possible to blind physicians, patients and personnel to the intervention, many of the outcomes assessed in this systematic review are objective in nature (e.g., 5-year survival) and are not likely to be influenced by performance or detection bias. Visual inspection of funnel plots found no clear evidence of publication bias. However, inadequate power for some clinical outcomes prevented an adequate analysis of bias. (Tables 3-5 Fig. 3 ). Significant heterogeneity was detected for this comparison (I 2 = 60%). A pooled analysis of 14 studies including 4,108 patients showed no statistically significant difference in disease-free survival (defined as the ; P = 0.18). Significant heterogeneity was detected for this comparison (I 2 = 48%). However, this was not the case when looking at the incidence of recurrence (rather than the time to recurrence). A pooled analysis of 22 studies including 6,176 patients showed that the odds of disease recurrence at follow-up were significantly reduced with mVATS compared to open lobectomy. The incidence of overall disease recurrence was 15% (451/2,950) of mVATS patients compared to 19% (600/3,226) in open lobectomy patients (OR 0.73; 95% CI, 0.61 to 0.87; P = 0.0005). Fourteen studies including a total of 3,693 patients reported on the proportion of patients who had local and distant disease recurrence at follow-up. There was no significant difference in local recurrence. Table 3 .
mVATS versus rVATS
One study (313 patients) comparing mVATS to rVATS reported on 5-year survival rates. 164 There was no statistically significant difference in 5-year survival rates. At 5 years, 73% (103/141) of mVATS patients were alive compared to 77% (133/172) of rVATS patients (OR 0.79; 95% CI, 0.47 to 1.33, P = 0.38). This study also reported on disease-free survival at 5 years. Sixty-five percent (92/141) of mVATS patients had no recurrence of cancer at 5 years compared to 73% (125/172) of patients in the rVATS group (OR 0.71; 95% CI, 0.44 to 1.14; P = 0.16). Two studies (2,059 patients) reported on 2-year survival rates. 85, 163 There was no statistically significant difference in 2-year survival rates. At 2 years, 86% (934/1,082) of mVATS patients were alive compared to 86% (838/977) of rVATS patients (OR 0.79; 95% CI, 0.47 to 1.33, P = 0.38). One study reported on disease-free survival at 2 years. 85 Eighty-three percent (131/158) of mVATS patients had no recurrence of cancer at 2 years compared to 92% (49/53) of patients in the rVATS group (OR 0.40; 95% CI, 0.13 to 1.19; P = 0.10). One study (211 patients) reported on disease recurrence, locoregional disease recurrence, and distant disease recurrence at 2 years follow-up. 85 There were no significant differences in disease Table 4 .
mVATS versus uVATS
Only one study (160 patients) comparing mVATS to uVATS reported on 3-year disease-free survival rates. 59 There was no statistically significant difference in 3-year disease-free survival rates. At 3 years, 88% (70/80) of mVATS patients were alive and disease-free compared to 92% (74/80) of uVATS patients (OR 0.57; 95% CI, 0.20 to 1.64, P = 0.30). Survival outcomes for the comparison mVATS versus uVATS are summarized in Table 5 . Tajiri 2007  3  0  0  3  Tane 2015  3  0  0  3  Tashima 2005  3  0  1  4  Tatsumi 2003  3  0  2  5  Trivino 2014  3  0  2  5  Usuda 2017  3  0  0  3  Veronesi 2010  3  2  0  5  Wang 2014  3  0  0  3  Wang 2016a  4 Due to a lack of data we were unable to make a comment regarding survival for uVATS versus mVATS.
Lymph Node Evaluation and Pathological Upstaging
Questions. Does VATS result in similar lymph node evaluation and pathological upstaging when compared to open lobectomy? What is the optimal MIS approach for lymph node evaluation and pathological upstaging?
mVATS versus Open Lobectomy
A pooled analysis of 28 studies including 29,341 patients showed no statistically significant difference in the mean number of dissected lymph nodes (MD −0.61; 95% CI, −1.51 to 0.29; P = 0.18). Significant heterogeneity was detected for this comparison (I 2 = 97%). Similarly, a pooled analysis of 15 studies including 6714 patients showed no statistically significant difference in the mean number of dissected lymph node stations (MD −0.10; 95% CI, −0.38 to 0.18; P = 0.49). Significant heterogeneity was detected for this comparison (I 2 = 97%). However, a pooled analysis of 15 studies including 16,367 patients showed that the odds of nodal upstaging were significantly reduced with mVATS compared to open lobectomy. Nodal upstaging occurred in 11% (906/8,135) of mVATS patients compared to 14% (1,175/8,232) of open lobectomy patients (OR 0.71; 95% CI, 0.58 to 0.87; P = 0.0009). Significant heterogeneity was detected for this comparison (I 2 = 57%). These outcomes are summarized in Table 3 .
mVATS Versus rVATS
A pooled analysis of 5 studies including 7,814 patients showed no statistically significant difference in the mean number of dissected lymph nodes between mVATS and rVATS (MD −0.82; 95% CI, −2.69 to 1.04; P = 0.39). Significant heterogeneity was detected for this comparison (I 2 = 74%). Similarly, a pooled analysis of 2 studies including 179 patients showed no statistically significant difference in the mean number of dissected lymph node stations (MD −0.20; 95% CI, −1.07 to 0.68; P = 0.66). Significant heterogeneity was detected for this comparison (I 2 = 69%). A pooled analysis of 6 studies including 18,216 patients showed no statistically significant difference in nodal upstaging between mVATS and rVATS. After lymph node sampling/dissection, 8% (1,258/14,724) of mVATS patients were upstaged compared to 10% (355/3,492) of rVATS patients (OR 1.02; 95% CI, 0.85 to 1.22; P = 0.87). No significant heterogeneity was detected for this comparison (I 2 = 18%). These outcomes are summarized in Table 4 .
mVATS versus uVATS
A pooled analysis of 10 studies including 1,789 patients showed no statistically significant difference in the mean number of dissected lymph nodes between mVATS and uVATS (MD 0.07; 95% CI, −1.24 to 1.38; P = 0.92). Significant heterogeneity was detected for this comparison (I 2 = 67%). One study that included 106 patients reported on nodal upstaging. 126 There was no statistically significant difference in nodal upstaging between mVATS and uVATS. After lymph node sampling/dissection, 27% (15/55) of mVATS patients were upstaged compared to 31% (16/51) of uVATS patients (OR 0.82; 95% CI, 0.35 to 1.90; P = 0.64). These outcomes are summarized in Table 5 . 
Adjuvant Chemotherapy
Questions. In patients requiring adjuvant therapy, will VATS allow more patients to receive and then complete this, compared to open lobectomy? What is the best MIS approach with respect to enabling delivery of adjuvant chemotherapy when indicated?
mVATS versus Open Lobectomy
Five studies including 6,930 patients reported on the proportion of patients who had adjuvant chemotherapy. 98, 102, 124, 156, 162 There was no statistically significant difference in the proportion of patients who had adjuvant chemotherapy. Fourteen 73%) . A visual inspection of the forest plot revealed two outliers. When these two studies were dropped from the analysis, there was still no statistically significant difference in the use of adjuvant chemotherapy. Thirteen percent (428/3,331) of mVATS patients had adjuvant chemotherapy compared to 13% (443/3,351) of open lobectomy patients (OR 0.99; 95% CI, 0.85 to 1.15; P = 0.89). No heterogeneity was detected for this analysis (I 2 = 0%). Two studies including 210 patients reported on the proportion of patients who failed to complete adjuvant chemotherapy. The odds of failing to complete adjuvant chemotherapy were significantly reduced by 62% in the mVATS group compared to open lobectomy. Thirty-four percent (38/111) of mVATS patients failed to complete adjuvant chemotherapy compared to 59% (58/99) of patients in the open lobectomy group (OR 0.38; 95% CI, 0.21 to 0.67; P = 0.0008). These outcomes are summarized in Table 3 .
mVATS versus rVATS
Only one study including 3,876 patients reported on the proportion of patients who had adjuvant chemotherapy. 163 There was no statistically significant difference in the proportion of patients who had adjuvant chemotherapy. Eleven percent (221/1,938) of mVATS patients had adjuvant chemotherapy compared to 13% (251/1,938) of rVATS patients (OR 0.87; 95% CI, 0.71 to 1.05; P = 0.14). These outcomes are summarized in Table 4 . Fig. 4 ). Significant heterogeneity was detected for this comparison (I 2 = 64%). With respect to specific complications, mVATS patients had significantly lower rates of cardiopulmonary complications (P < 0.0001), atrial fibrillation (P = 0.007), pneumonia (P < 0.0001), wound infection (P < 0.0001), air leak (P = 0.001), atelectasis (P < 0.0001), respiratory failure (P = 0.003), and 30-day mortality (P = 0.02) compared to patients who had open lobectomy. A pooled analysis of six studies (12,479 patients) found no difference between mVATS and open lobectomy in 90-day mortality rates (P = 0.12). Complications and adverse events are summarized in Table 3 .
A pooled analysis of 6 studies including 999 patients showed no statistically significant difference in complications between mVATS and rVATS. Twenty-five percent (138/545) of mVATS patients experienced complications compared to 24% (108/454) of patients in the rVATS group (OR 1.28; 95% CI, 0.75 to 2.17; P = 0.37). Significant heterogeneity was detected for this comparison (I 2 = 60%). With respect to specific complications, there was no significant difference between mVATS and rVATS in rates of atrial arrhythmia (P = 0.56), pneumonia (P = 0.26), prolonged air leak (P = 0.86), atelectasis (P = 0.46), respiratory failure (P = 0.09), and 30-day mortality (P = 0.85). Complications and adverse events are summarized in Table 4 .
mVATS versus uVATS
A pooled analysis of 6 studies including 1,010 patients showed a statistically significant difference in complications between mVATS and uVATS. Twelve percent (76/614) of mVATS patients experienced complications compared to 9% (31/396) of patients in the uVATS group (OR 1.77; 95% CI, 1.09 to 2.87; P = 0.02). No significant heterogeneity was detected for this comparison (I 2 = 0%). However, with respect to specific complications, there was no significant difference between mVATS and uVATS in rates of pneumonia (P = 0.86), prolonged air leak (P = 0.58), atelectasis (P = 0.74), and wound infection (P = 0.74). There were no reported cases of perioperative mortality or 30-day mortality in the studies that compared mVATS to uVATS. Complications and adverse events are summarized in Table 5 . 
mVATS versus Open Lobectomy
Pooled analyses show significantly reduced pain Visual Analog Scale (VAS) scores in mVATS patients compared to open lobectomy patients on postoperative day 1 (MD −0.68; 95% CI, −1.01 to 0.35; P < 0.0001; 4 studies; 429 patients), day 7 (MD −1.01; 95% CI, −1.46 to 0.56; P < 0.0001; 3 studies; 306 patients), day 14 (MD −0.37; 95% CI, −0.66 to 0.08; P = 0.01; 2 studies; 206 patients), day 30 (MD −0.84; 95% CI. −1.41 to 0.26; P = 0.004; 2 studies; 241 patients), and day 90 (MD −1.31; 95% CI, −1.80 to −0.82; P < 0.0001; 1 study, 103 patients).
One randomized study measured quality of life using the EuroQol5 tool. 19 Quality of life scores in mVATS patients were higher than open lobectomy patients at week 2 (MD −0.90; 95% CI, −0.90 to 8.50; P = 0.11), week 4 (MD 4.60; 95% CI, −0.07 to 9.27; P = 0.05), week 8 (MD 11.70; 95% CI, 7.05 to 16.35; P < 0.0001), week 12 (MD 3.10; 95% CI, −0.91 to 7.11; P = 0.13), week 26 (MD 3.60; 95% CI, −1.07 to 8.27, P = 0.13) and week 52 (MD 6.10; 95% CI, 1.40 to 10.80; P = 0.01). Three studies including 332 patients measured quality of life using global QoL tools. 19, 86, 171 Pooled analysis showed significantly higher quality of life at 1 year in mVATS patients compared to open lobectomy (SMD 0.42; 95% CI, 0.20 to 0.64; P = 0.001). No heterogeneity was detected for this comparison (I 2 = 0%). One study including 103 patients reported on an activities of daily living scale. 130 mVATS patients had significantly higher activities of daily living scores than open lobectomy patients at postoperative day 7 (MD 3.33; 95% CI, 2.01 to 4.65; P < 0.0001), 30 (MD 2.68; 95% CI, 1.77 to 3.59; P < 0.0001), and 90 (MD 1.38; 95% CI, 0.79 to 1.97; P < 0.0001).
Four studies involving a total of 340 patients reported on the 6-minute walk test, which is used to assess lung function. 13, 99, 107, 108 Three studies including 259 patients reported 6-minute walk test results for postoperative day 7. mVATS patients had a significantly higher FEV 1 than open lobectomy patients on postoperative day 7 with a mean difference of 3.04 L (95% CI, 1.01 to 5.08; P = 0.003). Significant heterogeneity was detected for this comparison I 2 = 76%. Pain, quality of life and overall function outcomes are summarized in Table 3 .
mVATS versus uVATS
Pooled analyses show significantly reduced pain visual analog scale (VAS) scores in uVATS patients compared to mVATS patients on postoperative day 1 (MD 0.49; 95% CI, 0.05 to 0.93; P = 0.03; 2 studies; 206 patients; I 2 = 68%), day 3 (MD 0.76; 95% CI, 0.58 to 0.94; P < 0.0001; 2 studies; 206 patients; I 2 = 29%), day 7 (MD 1.80; 95% CI, 1.63 to 1.97; P < 0.0001; 1 study;80 patients), and day 30 (MD 1.60; 95% CI, 1.43 to 1.77; P < 0.0001; 1 study; 80 patients). Two studies including 240 patients reported on the number of days per month of analgesic use. 57, 59 uVATS patients used analgesics for significantly fewer days per month than mVATS patients (MD 4.19; 95% CI, 3.77 to 4.61; P < 0.0001; I 2 = 0%). Only one study (that included 160 patients) reported on postoperative forced expiration volume. 59 mVATS patients had significantly lower FEV1 than uVATS patients with a mean difference of −0.23 L (95% CI, −0.34 to 0.12; P < 0.0001). Pain, quality of life, and overall function outcomes are summarized in Table 5 . 
Class IIB (Level C-LD)
Due to a lack of data we were unable to make a comment regarding pain, quality of life, and overall function for rVATS versus mVATS.
Length of Hospital Stay and Cost-Effectiveness
Questions. Does VATS result in a shorter hospital stay and cost savings when compared to open lobectomy? What is the optimal MIS approach with respect to length of hospital stay and cost-effectiveness?
mVATS versus Open Lobectomy
A pooled analysis of 35 studies including 36,776 patients showed that mVATS patients had a significantly reduced length of hospital stay compared to open lobectomy. The mean hospital stay for mVATS patients was 1.9 days less than open lobectomy patients (95% CI, −2.25 to -1.54; P < 0.0001). Significant heterogeneity was detected for this comparison (I 2 = 97%). Two studies including a total of 240 patients reported on the total cost of surgery in US dollars. 23, 37 The total cost for mVATS was significantly less than for open lobectomy (MD −1,951.52; 95% CI, −3171.91 to 731.13; P = 0.002). No heterogeneity was detected for this comparison (I 2 = 0%). One study including a total of 346 patients reported on the total cost of surgery in Euros. 29 The total cost for mVATS was significantly less than for open lobectomy (MD −155.00; 95% CI, −271.66 to 38.34; P = 0.009). These outcomes are summarized in Table 3 .
rVATS versus Open Lobectomy
A pooled analysis of 2 studies including 7,516 patients showed that rVATS patients had a significantly reduced length of hospital stay compared to open lobectomy. The mean hospital stay for rVATS patients was 0.82 days less than open lobectomy patients (95% CI to 1.07 to -0.57; P < 0.0001). No significant heterogeneity was detected for this comparison (I 2 = 0%).
uVATS versus Open Lobectomy
Only one study including 53 patients showed that uVATS patients had a significantly reduced length of hospital stay compared to open lobectomy. 88 The mean hospital stay for uVATS patients was 2.03 days less than open lobectomy patients (95% CI −3.17 to -0.89; P = 0.0005).
mVATS versus rVATS
A pooled analysis of 5 studies including 7,752 patients showed no statistically significant difference in length of hospital stay between mVATS and rVATS. The mean hospital stay for mVATS patients was 0.16 days less than rVATS patients (95% CI, −0.81 to 0.48; P = 0.62). Significant heterogeneity was detected for this comparison (I 2 = 58%). Two studies including a total of 4,268 patients reported on the total cost of surgery in US dollars. 37, 147 The total cost for mVATS was significantly less than for rVATS (MD −4238.03; 95% CI, −5507.27 to 2968.79; P < 0.0001). No heterogeneity was detected for this comparison (I 2 = 0%). These outcomes are summarized in Table 4 .
mVATS versus uVATS.
A pooled analysis of 7 studies including 1,269 patients showed no statistically significant difference in length of hospital stay between mVATS and uVATS. The mean hospital stay for mVATS patients was 0.38 days more than uVATS patients (95% CI, −0.12 to 0.88; P = 0.14). Significant heterogeneity was detected for this comparison (I 2 = 48%). 
Discussion
The first reports of minimally invasive lobectomy were in the early 1990s. 1 In the ensuing years several centers reported their experience with VATS lobectomy, and approaches and definitions of VATS lobectomy became more standardized as reported in the landmark multicenter CALGB 39802 study of VATS lobectomy. 178 Despite significant literature including almost 2,000 reports since 1992, the adoption of VATS lobectomy is still relatively low. A recent analysis of the National Cancer Database suggested that out of 55,972 lobectomies performed in 905 hospitals, only 30.5% were performed by VATS. 179 VATS rates, however, varied with centers in the highest quintile performing 76% of cases with VATS compared to 0.6% in the lowest quintile.
The reasons for the low adoption are likely multifactorial and include 1) a relative paucity of randomized trials supporting the VATS approach. Of those trials that are available, these have focused mostly on short-term outcomes and the studies may have been underpowered to show true differences between techniques. 2) The surgeons who have adopted VATS have lacked equipoise to randomize their patients to open operations, and patients are also reluctant to be randomized between an invasive and minimally invasive technique when both are available.
3) The preponderance of data has therefore been with retrospective studies a well as some prospective and large registry studies. 4) Minimally invasive approaches have also evolved from the mVATS approach originally described, to rVATS, which was first reported in 2003 180 ; and uVATS which was first reported in 2011. 181 Although many surgeons have transitioned from mVATS to these other MIS approaches, several centers have also transitioned directly to rVATS or uVATS from thoracotomy with strong advocates for each approach.
Our systemic review and meta-analysis first asked the question about differences between a minimally invasive approach and thoracotomy for lobectomy. Since mVATS has been utilized by surgeons for longer, there are more studies than rVATS and uVATS, many with long-term follow-up available for review. Additionally, mVATS can be considered the gold-standard minimally invasive approach, to which rVATS and uVATS can be compared.
Prior to performing this review, the perceptions of many surgeons was that mVATS would be associated with decreased morbidity, less pain, faster return to normal activity, and improved ability to receive adjuvant therapy (if required) compared to thoracotomy. Oncological outcomes are generally considered to be similar. Our systemic review supported many of these arguments. Of note, the meta-analysis allowed us to compare over 88,000 patients pooled from several studies, demonstrating a lower overall complication rate when comparing mVATS to thoracotomy. Similarly, when looking at a number of different specified complications there were statistically significant differences favoring mVATS over thoracotomy for virtually all of these comparisons. In many cases the actual numerical differences were small; for instance, the rate of pneumonia was 4.1% after VATS compared to 5.4% after thoracotomy. This supports the use of a meta-analysis approach, since it would require a very large randomized trial to confirm a small difference of 1.3%.
Length of hospital stay was also significantly lower for mVATS, by almost 2 days compared to thoracotomy when looking at several studies with over 36,000 patients combined. This has implications for cost-effectiveness. However, these studies do not take different pathways of care that might be present into account, or the impact that enhanced recovery after surgery programs might have on this variable.
Oncological effectiveness can be looked at in a number of ways that include lymph node evaluation, disease-free survival and most importantly overall survival. With respect to lymph node evaluation the total number of lymph nodes removed, the number of lymph node stations evaluated and the incidence of nodal upstaging all reflect effectiveness. Many open surgeons argue that oncological effectiveness is superior with thoracotomy. Our analysis did not show a difference for lymph node counts or nodal stations evaluated, but, there was more nodal upstaging with thoracotomy at 14.3% compared to 11.1% after mVATS. However, this did not translate into a difference in recurrence-free survival, and overall survival in fact, favored mVATS over thoracotomy when looking at both 3-and 5-year (71.5% versus 66.7%) overall survival rates. These conclusions, however should be interpreted with some caution. It is possible that there was some imbalance with surgeons selecting larger and more central tumors for thoracotomy. Such patients may be more likely to have pathological upstaging, and potentially have worse survival. Supporting these conclusions however are that we did not include patients who received neoadjuvant therapy and so presumably had similar clinical stage Pain, quality of life (QOL) and function are difficult parameters to measure. There are many subjective instruments available for these outcomes and the challenge for the meta-analysis was finding studies that used the same instruments across several studies. Additionally, outcomes can be measured at different time-points which also created difficulties in finding consistent studies. For pain, one of the most commonly used instruments was the VAS score. There were a few studies that recorded VAS at a number of different time-points and these all favored the use of mVATS over thoracotomy. A randomized trial using a different pain score also demonstrated superiority with mVATS. 19 This resulted in the IIa recommendation favoring mVATS for pain control compared to thoracotomy. QOL and function were perceived to be better with mVATS, but the level of evidence supporting this was lower resulting in IIb recommendations.
Although it has been argued that mVATS patients are more likely to receive adjuvant therapy than thoracotomy patients, our analysis did not support this. The only significant difference that we identified was that after a decision to give adjuvant chemotherapy was made, was that mVATS patients are more likely to complete their planned course of chemotherapy.
Cost-effective analysis can be challenging to assess and depend on what costs are inputted into the analysis. Another consideration is that depending on the country, different currencies are used, making it difficult to include several studies in the same meta-analysis. There were two studies that measured cost in US dollars when comparing mVATS to thoracotomy. The differences significantly favored mVATS.
When making comparisons between different MIS approaches there are some considerations. Although rVATS is gaining in popularity there are less centers using this approach, and so fewer publications are available. Although a few studies with long-term outcomes have been reported, most studies have focused on short-term outcomes. uVATS is the newest approach, and so there is a paucity of studies with comparative long-term follow-up. Furthermore, there is currently no consensus or standard definition of a uVATS approach.
Common perceptions among surgeons are that rVATS is more expensive than mVATS and that lymph node evaluation is superior with the rVATS approach. With respect to uVATS, advocates feel that there is less pain and fewer complications compared to mVATS. Our meta-analysis did not demonstrate a difference between mVATS and rVATS with respect to adverse events. When comparing mVATS to uVATS, six studies were identified, and the overall effect was that there were significantly fewer complications with uVATS (Fig. 5) . Of note, all of these studies were from Asia. Heterogeneity was low (I 2 = 0) and the practice is not necessarily representative of that in North America or Europe. Furthermore, we have been careful to identify and when necessary exclude studies from the data analysis that are comparing different intra-thoracic surgical techniques rather than different surgical access approach. 70 When looking at specific complications, there were no differences between mVATS and uVATS. Additionally, there was one randomized European study that was not included in the meta-analysis comparing adverse events since only one complication was reported in the entire study and differences were therefore not significant. 126 For these reasons, the consensus panel felt that mVATS, uVATS, and rVATS had similar rates of adverse events. Additionally, length of hospital stay was not different between the three MIS approaches.
Contrary to statements advocated by rVATS enthusiasts, we did not see a difference in the number of lymph nodes dissected, lymph node stations evaluated and nodal upstaging when comparing rVATS to mVATS. Similarly, there were no differences between uVATS and mVATS for lymph node evaluation. A few studies compared survival and recurrence between rVATS and mVATS and no difference was seen. No comment can be made on comparisons between uVATS and mVATS with respect to survival and recurrence due to a lack of studies with long-term follow-up for these outcomes.
There were a few studies using the VAS score to assess pain comparing uVATS to mVATS and these favored uVATS at early time-points. The use of analgesics was also lower in two studies comparing uVATS and mVATS. A IIb recommendation favoring uVATS to mVATS was given.
With respect to cost-effectiveness rVATS was found to be significantly more expensive than mVATS. Otherwise there were no significant differences between the MIS approaches in any other outcome that was assessed.
Conclusions
In conclusion, we have performed an extensive systemic review and meta-analysis comparing mVATS to open lobectomy, and the most popular MIS approaches to each other. mVATS has been reported for over 25 years and a large number of studies with several thousand patients have been included in comparisons between mVATS and open lobectomy. However, only 7 of the 145 included studies were randomized trials. In addition to the general limitations of meta-analysis, it is hard to control for surgeon specific biases (e.g., treating smaller and peripheral tumors with an MIS approach), and institutional biases where some surgeons will use an open and others an MIS approach. With these limitations in mind, our analysis suggests that the mVATS approach is superior to thoracotomy, particularly with respect to adverse events, pain control and perhaps improved survival. With respect to the optimal MIS approach, fewer studies are available to make definitive statements. Robotic VATS may be more expensive than mVATS, but otherwise does not demonstrate superiority or inferiority compared to mVATS. There is a suggestion that uVATS may be associated with lower adverse events and pain. It is our goal that the extensive analysis provided in the manuscript and appendix will assist future investigators in planning new trials to explore differences between these techniques.
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